Has Roy Cho, MD received payments from drug or device companies?

Yes. Drug and device makers reported $121,519 in general payments to Roy Cho, MD across 233 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Roy Cho, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Roy Cho, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Roy Cho, MD

Internal Medicine · Minneapolis, MNNPI 1063705580

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (41.0%), consulting fees and education — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by AstraZeneca at 45.6% of the total. Among internal medicine clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$121,519in general payments, 2019–2025

Across 233 payments — averaging $521.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$55K
Merit Medical Systems Inc$18K
Olympus America Inc.$18K
Olympus Corporation Of The Americas$17K
Intuitive Surgical$7K
Visionair Solutions, LLC$4K
plus $3K from 8 others

What the payments were for

Consulting fees$35,34029%
Speaking & faculty fees$49,77841%
Travel & lodging$13,62711%
Food & beverage$4,5154%
Education$18,26015%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	83	$55,405
Merit Medical Systems Inc	18	$17,905
Olympus America Inc.	38	$17,807
Olympus Corporation Of The Americas	25	$17,394
Intuitive Surgical	54	$6,822
Visionair Solutions, LLC	1	$3,600
Gyrus ACMI, Inc.	2	$900
Johnson & Johnson	3	$493
Covidien LP	1	$430
Veran Medical Technologies, Inc.	2	$375
Noah Medical Corporation	2	$179
Medtronic	1	$114
ERBE USA Inc	1	$70
Bayer	2	$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

IMFINZI$49,568
Spiration Valve System$19,035
AERO Stent & del system$14,263
Da Vinci Surgical System$5,727
Visionair Patient Specific Airway Stent$3,600
EVES EUS ULTRASOUND BRONCHOFIBERVIDEOSCOPE$3,285
BIG60 Inflation device$1,425
MAXXWIRE$1,425
superDimension$544
AERO Stent and Delivery System$475
MONARCH$381
SPiN Vision Scope, 4.0mm OD, 2.0mm WC$102
GALAXY$100

How this compares

$121,519 in reported general payments places this provider in the 95th percentile of 1,924 internal medicine providers in Minnesota.

See all internal medicine providers in Minnesota →

Medicare billing

Part B allowed, 2024

$41,280

Medicare patients

160

Services billed

320

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	42	$46,094
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth	20	$1,531
Albuterol Sulfate HfaAlbuterol Sulfate	21	$1,190
Azithromycin	33	$1,144

Paid to pharmacies, not to this prescriber.

Other internal medicine in Minneapolis

Mustafa ArainMinneapolis$44K
Noah WillifordMinneapolis$42K
Kathryn AndersonMinneapolis$34K
Nadeem KhanMinneapolis$23K
Oluwaremilekun Tolu AkinnawoMinneapolis$21K
Beth ThielenMinneapolis$14K
Amir MoheetMinneapolis$12K
Timothy SchackerMinneapolis$11K
Bassem RouphaelMinneapolis$10K
Zaid GheithMinneapolis$10K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →